Alan F. List

Alan List is a pioneering MDS researcher who led the development of lenalidomide for deletion 5q MDS and subsequently directed the MEDALIST trial establishing luspatercept for transfusion-dependent low-risk MDS with ring sideroblasts. His research elucidated the mechanisms by which SF3B1 splicing factor mutations cause ring sideroblast formation and impair erythroid maturation. He contributed to fundamental understanding of the 5q minus syndrome and the molecular basis for lenalidomide's exquisite activity in this condition. His career has produced multiple MDS drug approvals.